Myovant Sciences Ltd.
MYOV
MYOV was delisted on the 9th of March, 2023.
52 hedge funds and large institutions have $621M invested in Myovant Sciences Ltd. in 2016 Q4 according to their latest regulatory filings, with 52 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
QF
QVT Financial
New York
|
+$431M |
| 2 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$37M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$17.4M |
| 4 |
DM
Deerfield Management
New York
|
+$17.3M |
| 5 |
SCM
Scopia Capital Management
New York
|
+$9.48M |
Top Sellers
MYOV Hedge Fund Activity: Q4 2016 in Review
52 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Myovant Sciences Ltd. (MYOV) for Q4 2016, worth a combined $621M.
Buyers outnumbered sellers: 52 funds opened new MYOV positions and 0 closed out — a net gain of 52 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was QVT Financial, opening a new position worth an estimated $431M.
- 52 institutional investors held Myovant Sciences Ltd. (MYOV) as of Q4 2016, up from 0 in Q3 2016.
- Funds reported $621M of Myovant Sciences Ltd. stock for Q4 2016.
- 52 funds opened new Myovant Sciences Ltd. positions in Q4 2016 and 0 closed out, a net change of +52 holders.
- The largest Myovant Sciences Ltd. buyer in Q4 2016 was QVT Financial, an estimated $431M added.
Based on aggregated 13F filings for Q4 2016.